Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020069372 - MOLÉCULES MULTISPÉCIFIQUES CSF1R/CCR2


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2019/053544 E2070-7018WO
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
27 September 2019 27 September 2018
Applicant
ELSTAR THERAPEUTICS, INC.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
This International Searching Authority found multiple inventions in this international application, as follows:
1. claims: 1-54(completely); 70-81(partially)
A multispecific molecule comprising: (i) an anti-CSFlR binding moiety (e.g., an anti-CSF1R antibody molecule); (ii) an anti-CCR2 binding moiety (e.g., an anti-CCR2 antibody molecule); and (iii) a TGF-beta inhibitor
2. claims: 55-60(completely); 70-81(partially)
An antibody molecule that binds to CSF1R,  characterized by its variable chain sequences (CDRs)
3. claims: 61, 62(completely); 67-81(partially)
An antibody molecule that binds to CCR2,  characterized by its variable chain sequences (CDRs)
4. claims: 63-66(completely); 67-81(partially)
An antibody molecule that binds to PD-L1  characterized by its variable chain sequences (CDRs)
1.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.
As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-54(completely); 70-81(partially)
Remark on Protest
The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.
The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
CSF1R/CCR2 MULTISPECIFIC ANTIBODIES

5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     1    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61P 35/00 (2006.01)i; C07K 16/28 (2006.01)i; C07K 16/46 (2006.01)i; A61K 39/00 (2006.01)n
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61P; A61K; C07K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
GULAM ABBAS MANJI ET AL, "Current and Emerging Therapies in Metastatic Pancreatic Cancer", CLINICAL CANCER RESEARCH,Vol. 23, No. 7, April 2017 (2017-04), page 1670-1678,
XP055650459
1
Y
the whole document
2-54,70-81
(2)
Y
B. VIJAYALAKSHMI AYYAR ET AL, "Coming-of-Age of Antibodies in Cancer Therapeutics", TRENDS IN PHARMACOLOGICAL SCIENCES.,Vol. 37, No. 12, December 2016 (2016-12), page 1009-1028,
XP055650464
2-54,70-81
the whole document
(3)
Y
WILLIAM R. STROHL, "Current progress in innovative engineered antibodies", PROTEIN & CELL,Vol. 9, No. 1, 18 August 2017 (2017-08-18), page 86-120,
XP055502882
2-54,70-81
the whole document
(4)
X,P
WO 2018195283 A1 (ELSTAR THERAPEUTICS INC [US]) 25 October 2018 (2018-10-25)
1-54
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2018195283 A1
25 October 2018
AU 2018256406 A1
CA 3058944 A1
CN 110709422 A
EP 3612563 A1
WO 2018195283 A1
17 October 2019
25 October 2018
17 January 2020
26 February 2020
25 October 2018
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
13 December 2019
Date of mailing of the international search report:
17 February 2020
Authorized officer:
Nauche, Stéphane
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E